Halozyme Therapeutics: 3Q Earnings Snapshot

November 12, 2019 GMT

SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Tuesday reported a loss of $25 million in its third quarter.

On a per-share basis, the San Diego-based company said it had a loss of 17 cents.

The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 12 cents per share.

The biopharmaceutical company posted revenue of $46.2 million in the period, also missing Street forecasts. Three analysts surveyed by Zacks expected $58.8 million.

Halozyme Therapeutics expects full-year revenue in the range of $195 million to $205 million.

Halozyme Therapeutics shares have risen 15% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $16.77, a rise of 11% in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on HALO at https://www.zacks.com/ap/HALO